Indoor radiator burns can cause significant morbidity and mortality, especially in vulnerable patients. However, the epidemiology and clinical outcomes are poorly characterized. A retrospective study ...of all radiator burns referred to a tertiary regional burns centre between 2013-2019 was conducted. Four hundred and forty-seven patients (median age 25.6 years, male:female ratio 1.4:1) were referred; 109 (24%) admitted, 201 (45%) managed in outpatients and 137 (31%) managed locally. The incidence of burns leading to referral was 0.65/100,000/year, but increased annually. Contact burns consisted of 99.6%. Age distribution was bimodal: <5 years (43%), >65 years (27%), although all ages were affected. Median TBSA was 0.75% (0.1-11.5%), but 79% had injuries <2%. Childhood burns were predominantly superficial dermal grab injuries, usually manageable as outpatients. Elderly patients had larger burns usually secondary to falls or impaired sensorium, and were more likely to die (p<0.05). Burns due to impaired sensorium were deeper and more likely to require surgery (p<0.05). Sixty-three (14%) patients required surgery. Thirty-day mortality was 1.1%. Age was the only significant predictor of mortality. This study quantifies the epidemiology and outcomes of a growing problem. It identifies at risk populations (extremes of age), and important features of the clinical assessment.
If approved for use in young males in the United States, prophylactic human papillomavirus (HPV) vaccine may reduce the incidence of HPV-related disease in vaccinated males and their sexual partners. ...We aimed to characterise heterosexual men's willingness to get HPV vaccine and identify correlates of vaccine acceptability.
Participants were from a national sample of heterosexual men (n=297) aged 18-59 y from the United States who were interviewed in January 2009. We analysed data using multivariate logistic regression.
Most men had not heard of HPV prior to the study or had low HPV knowledge (81%; 239/296). Most men had heard of HPV vaccine prior to the study (63%; 186/296) and 37% (109/296) were willing to get HPV vaccine. Men were more willing to get vaccinated if they reported higher perceived likelihood of getting HPV-related disease (OR 1.80, 95% CI 1.02 to 3.17), perceived HPV vaccine effectiveness (OR 1.86, 95% CI 1.22 to 2.83) or anticipated regret if they did not get vaccinated and an HPV infection later developed (OR 2.01, 95% CI 1.40 to 2.89). Acceptability was also higher among men who thought (OR 9.02, 95% CI 3.45 to 23.60) or who were unsure (OR 2.67, 95% CI 1.30 to 5.47) if their doctor would recommend they get HPV vaccine if licensed for males.
Men had low HPV knowledge and were moderately willing to get HPV vaccine. These findings underscore the need for HPV educational efforts for men and provide insight into some of the factors that may affect the HPV vaccination decision making process among men.
Half-lifes (
T
1/2
) of exotic neutron-rich isotopes of Ba, La, Ce, Pr, and Nd were measured at the RIKEN Nishina Center. The experimental setup consisted of the BigRIPS in-flight separator for ion ...selection identification, the Advance Implantation Detector Array (AIDA) for ions and β detection, and the BRIKEN detector for neutron counting. Using this setup, 4 new
T
1/2
have been measured for the first time, and 38
T
1/2
have been remeasured with improved precision in several cases. These new experimental data should help to constrain theoretical models for calculations of
T
1/2
. The status of the experimental analysis and preliminary results are provided in this contribution.
At the RIKEN Nishina Center, exotic neutron-rich isotopes of Ba, La, Ce, Pr, and Nd were measured. This work reports their half-lives (
T
1/2
) and β-delayed neutron-emission probabilities (
P
xn
). ...The setup consisted of the BigRIPS in-flight separator for particle identification, the Advanced Implantation Detector Array (AIDA) for ions and β detection, and the BRIKEN neutron counter for neutron detection. Using this arrangement, 4 new
T
1/2
and 14 new
P
1
n
were measured. Furthermore, 38
T
1/2
and 2
P
1
n
values were remeasured, decreasing the uncertainties for some of them. In addition to improving predictions of nucleosynthesis models that describe the production of the rare-earth peak at A ∼ 160 via the r-process, these additional experimental data should help to constrain theoretical models for calculations of
T
1/2
and
P
xn
in this region.
Kidney transplantation is the treatment of choice in pediatric patients with end‐stage renal disease. This population presents technical challenges particularly in those less than 20 kg due to ...anomalous anatomy, vascular access issues prior to transplantation, and a generally small size for age. Standard allograft outflow is usually achieved utilizing the iliac veins or IVC. When use of the iliocaval system is not feasible, alternative anastomosis must be considered. Herein, we report a case of a pediatric kidney transplantation where successful allograft outflow was achieved using the SMV when he was found to have an atretic IVC intraoperatively. In this setting, use of the portal system was required to achieve adequate allograft outflow. We created a donor iliac graft for added length to anastomose the renal vein with the SMV. In the setting of IVC occlusion with poor drainage, we utilized a patent vessel with larger caliber for outflow to reduce the risk of high venous pressures, allograft failure, venous rotation, and thrombosis. We conclude that the SMV may serve as an alternative outflow tract in the small pediatric patient and provides the vessel caliber needed to reduce the risks of complications.
Background/Aims: Our study examined whether patient characteristics, beliefs and decision-making styles were associated with uptake of genomic testing for breast cancer recurrence risk. Methods: ...Participants were 132 early-stage breast cancer patients eligible for the Oncotype DX genomic test. We interviewed patients in 2009-2010 and obtained information from medical charts. Results: Half of the women eligible for genomic testing for breast cancer recurrence risk received it. The most common reason for not getting the test was that women's physicians did not offer it (80%). Test recipients were more likely to be unsure about receiving chemotherapy treatment compared to women who did not receive the test (p < 0.05). Women who received the test had less advanced disease pathologies, recalled a lower objective recurrence risk, perceived lower recurrence risk, and were slightly younger (all p < 0.05). Most women who described their decision-making style as active received the test (75%), whereas few women who described their style as passive received the test (12%) (p < 0.01). Conclusion: In the university clinic we studied, genomic testing appeared to be more common among patients who may benefit most from the information provided by results, but confirmation in larger studies is needed.
PDF
